Abstract
Background Obesity is a modifiable risk factor for coronavirus(COVID-19)-related mortality. We estimated excess mortality in obesity, both “direct”, through infection, and “indirect”, through changes in healthcare, and also due to potential increasing obesity during lockdown.
Methods In population-based electronic health records for 1 958 638 individuals in England, we estimated 1-year mortality risk(“direct” and “indirect” effects) for obese individuals, incorporating: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)population infection rate, and (iii)relative impact on mortality(relative risk, RR: 1.2, 1.5, 2.0 and 3.0). Using causal inference models, we estimated impact of change in body-mass index(BMI) and physical activity during 3-month lockdown on 1-year incidence for high-risk conditions(cardiovascular diseases, CVD; diabetes; chronic obstructive pulmonary disease, COPD and chronic kidney disease, CKD), accounting for confounders.
Findings For severely obese individuals (3.5% at baseline), at 10% population infection rate, we estimated direct impact of 240 and 479 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 383 to 767 excess deaths, assuming 40% and 80% will be affected at RR=1.2. Due to BMI change during the lockdown, we estimated that 97 755 (5.4%: normal weight to overweight, 5.0%: overweight to obese and 1.3%: obese to severely obese) to 434 104 individuals (15%: normal weight to overweight, 15%: overweight to obese and 6%: obese to severely obese) individuals would be at higher risk for COVID-19 over one year.
Interpretation Prevention of obesity and physical activity are at least as important as physical isolation of severely obese individuals during the pandemic.
Research in context
Evidence before this study
Evidence before this study We searched PubMed, medRxiv, bioRxiv, arXiv, and Wellcome Open Research for peer-reviewed articles, preprints, and research reports on obesity, excess mortality and change in body-mass index in the coronavirus disease 2019 (COVID-19), using the search terms “obesity”, “coronavirus”, “COVID-19”, and similar terms, and “mortality”, up to June 15, 2020. We found no prior studies of excess deaths in obese individuals due to COVID-19 pandemic, and no studies of long-term estimates or the relative impact of COVID-19 on mortality. Moreover, there were no studies of change in body-mass index during lockdown periods. Without these data, it is difficult to make specific recommendations in obese people at individual or population level during the pandemic.
Added value of this study
Added value of this study We estimated excess COVID-19-related mortality in severely obese individuals, targeted in physical distancing and isolation policies in UK government guidance. Assuming 10% infection rate, we estimated a direct impact of 240 to 479 excess deaths in England and indirect effect of 383 to 767 excess deaths. On the other hand, we estimated that between 97 755 and 434 104 individuals may develop high-risk conditions for COVID-19 mortality during a 3-month lockdown due to change in body-mass index and physical activity.
Implications of all the available evidence
Implications of all the available evidence These analyses support COVID-19 and non-COVID-19 impact assessment in policy planning during the pandemic. The implications of distancing and isolation measures on incidence and mortality from chronic diseases, particularly relating to obesity, needs to be considered in clinical practice, public health and research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AB is supported by research funding from NIHR, British Medical Association, Astra-Zeneca and UK Research and Innovation. AGL is supported by funding from the Wellcome Trust, National Institute for Health Research (NIHR) University College London Hospitals, NIHR Great Ormond Street Hospital Biomedical Research Centres and the Health Data Research UK Better Care Catalyst Award. HH is an NIHR Senior Investigator and is funded by the NIHR University College London Hospitals Biomedical Research Centre. HH and RJBD are supported by Health Data Research UK (grant No. LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome Trust. HH, AB and RJBD are supported by The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074. RJBD is supported by: (1) NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London, London, U.K. (2) The National Institute for Health Research University College London Hospitals Biomedical Research Centre. (3) The UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare. (4) the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at Kings College Hospital NHS Foundation Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was by the Independent Scientific Advisory Committee (18_010R) of the UK Medicines and Healthcare products Regulatory Agency in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
CPRD data are available by ISAC application and approval.
